Literature DB >> 2163322

Production of interleukin-6 by anterior pituitary cells is stimulated by increased intracellular adenosine 3',5'-monophosphate and vasoactive intestinal peptide.

B L Spangelo1, P C Isakson, R M MacLeod.   

Abstract

Interleukin-6 (IL-6) is an inflammatory cytokine that is produced by a variety of cells and tissues. We recently demonstrated that IL-6 is produced by anterior pituitary cells in response to the bacterial endotoxin lipopolysaccharide and phorbol diester in vitro. Lipopolysaccharide (0.01-100 ng/ml) increased, whereas dexamethasone (0.1-100 nM) decreased, IL-6 production by anterior pituitary cells in vitro as measured by the 7TD1 cell growth factor assay. In addition, we now report that IL-6 production by anterior pituitary cells is stimulated by agents that elevate intracellular cAMP concentrations. Exposure of anterior pituitary cells to (Bu)2cAMP (0.01-10 mM), prostaglandin E2 (1.0-1000 nM), forskolin (50-1000 nM), or cholera toxin (0.25-250 ng/ml) for 6 h resulted in concentration-related increases in the production of IL-6, which, in the cases of forskolin and cholera toxin, correlated well with increased intracellular cAMP concentrations. Vasoactive intestinal peptide (1-1000 nM), which stimulates adenylate cyclase activity in the anterior pituitary, caused a concentration-related enhancement of IL-6 production that was unaffected in the presence of 10-100 nM somatostatin. In contrast, GH-releasing factor had no effect on IL-6 production. These data suggest that anterior pituitary cells produce IL-6 in response to increased intracellular cAMP, and that the neuropeptide vasoactive intestinal peptide may act to regulate IL-6 production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163322     DOI: 10.1210/endo-127-1-403

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells.

Authors:  C Ishioka; A Yoshida; H Kimata; H Mikawa
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 2.  Physiological and pathological roles of interleukin-6 in the central nervous system.

Authors:  D L Gruol; T E Nelson
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

3.  Serotonin increases interleukin-6 release and decreases tumor necrosis factor release from rat adrenal zona glomerulosa cells in vitro.

Authors:  P K Ritchie; H H Knight; M Ashby; A M Judd
Journal:  Endocrine       Date:  1996-12       Impact factor: 3.633

4.  Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors.

Authors:  A R Rezai; A Rezai; O Martínez-Maza; M Vander-Meyden; M H Weiss
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures.

Authors:  E Arzt; G Stelzer; U Renner; M Lange; O A Müller; G K Stalla
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

6.  Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP.

Authors:  D L Hoover; A M Friedlander; L C Rogers; I K Yoon; R L Warren; A S Cross
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

7.  Pituitary Folliculo-Stellate-Like Cells Stimulate Somatotroic Pituitary Tumor Growth in Nude Mice.

Authors:  Chiaki Koyama; Hirokazu Matsumoto; Takafumi Sakai; Katsumi Wakabayashi; Akihiro Ito; Ernest F. Couch; Kinji Inoue
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.